Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice

Pediatric Infectious Disease Journal

Volumn 33, Issue 8, 2014, Pages 858-864

  Azzari, Chiara ^a   Martinón Torres, Federico ^b,c   Schmitt, Heinz Josef ^d   Dagan, Ron ^e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Instituto de Salud Carlos III   (Spain)

^c Vaccine Research Unit Healthcare Research Institute of Santiago   (Spain)

^d PFIZER INC   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Invasive pneumococcal diseases; PCV13; Pneumococcal conjugate vaccine; Pneumococcal diseases

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVENAR13; VACCINE;

ADOLESCENT; ADULT; CHILD; EUROPE; HUMAN; IMMUNOLOGY; INFANT; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; EUROPE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84905920154     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000328     Document Type: Conference Paper

References (82)

1. GlaxoSmithKline Biologicals s.a. Synoflorix summary of product characteristics. [European Medicines Agency]. 2013. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000973/WC500054346.pdf. Accessed March 4, 2013.
2. Electronic Medicines Compendium. Prevenar 13. [eMC]. September, 2013. Available at: http://www.medicines.org.uk/emc/medicine/22689/SPC/Preve nar+13+suspension+for+injection/. Accessed November 14, 2013.
3. Advisory Committee on Immunization Practices (ACIP). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-819.
4. Diavegia. Anaprhteo Eto Lialiktyo. [Diavegia]. December 21, 2011. Available at: http://static.diavgeia.gov.gr/doc/45OOE-2EI. Accessed November 19, 2013.
5. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
6. Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30:127-151.
7. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
8. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197-e209.
9. Fitzwater SP, Chandran A, Santosham M, et al. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31:501-508.
10. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
11. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121:253-260.
12. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369: 155-163.
13. Public Health England. [Public Health England]. April 26, 2013. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/Pneumococcal/ EpidemiologicalDataPneumococcal/ CurrentEpidemiologyPneumococcal/. Accessed May 14, 2013.
14. Georgakopoulou T, Menegas D, Tzanakaki G, et al. Epidemiology of bacterial meningitis in Greece, in the era of conjugate vaccines: a 7 years review 2005-2011. Paper presented at: 52nd ICAAC; San Francisco, CA, USA; September 9-12, 2012. 2012. Available at: http:// www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=d201a978-86b7-4126-b4eb-dce82709451f&cKey= fd9b920f-2dad-4c23-9dba-3f0f20b33da8&mKey=%7b6B114A1D-85A4-4054-A83B- 04D8B9B8749F%7d. Accessed June 13, 2013.
15. van der Linden M, von Kries R, Imohl M. Effects of three years of immunization with higher valent pneumococcal conjugate vaccines on serotype distributions among reported IPD cases in German children and adults. Paper presented at: 52nd ICAAC; September 9-12, 2012; San Francisco, CA, USA,. September 10, 2012. Available at: http:// www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=becf1b8c-545a-4792-ac02-4a9cb31fdf7b&cKey= bb809851-e003-4b87-8957-043e6ed60add&mKey=%7b6B114A1D-85A4-4054-A83B- 04D8B9B8749F%7d. Accessed October 8, 2013.
16. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease in children in Madrid, 2010-2011 (Heracles study). Paper presented at: 8th International Symposium on pneumococci and pneumococcal diseases; March 11-15, 2012; Iguacu Falls, Brazil. 2012. Available at: http://www2.kenes.com/ ISPPD/Scientific/Documents/FinalAbstractbook. pdf. Accessed June 13, 2013.
17. Moore M, Link-Gelles R, Farley MM, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, US, 2010-11. Paper presented at: ID Week 2012; October 17-21, 2012; San Diego, CA. 2012. Available at: https://idsa.confex.com/idsa/2012/webprogram/ Paper36569.html. Accessed June 13, 2013.
18. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203-207.
19. Statens Serum Institute. Invasive pneumococcal disease and PCV coverage 2012. [EPI-NEWS, No 19, 2013]. 2013. Available at: http://www.ssi.dk/ English/News/EPI-NEWS/2013/No%2019%20-%202013.aspx. Accessed August 21, 2013.
20. Hsu K, Loughlin A, Stevenson A, et al. Early evidence of 13 valent pneumococcal conjugate vaccine impact on carriage of vaccine serotypes. Paper presented at: IDSA Annual meeting; October 20-23, 2011; Boston, USA. 2013. Available at: https://idsa.confex.com/idsa/2011/webprogram/ Paper31981.html. Accessed October 8, 2013.
21. Felix S, Valente C, Tavares DA, et al. Temporal trends of serotypes included in the novel 13-valent pneumococcal conjugate vaccine (PCV13) among young children from Portugal. Paper presented at: 8th International Symposium on Pneumococci and Pneumococcal Diseases; March 11-15, 2012; Iguacu Falls, Brazil. 2012. Available at: http:// www2.kenes.com/ISPPD/Scientific/Documents/ FinalAbstractbook.pdf. Accessed October 8, 2013.
22. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). Paper presented at: 51st ICAAC; September 17-20, 2011; Chicago, USA. 2011. Available at: http:// www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=b0b69d8d-27d1-43f4-8f4e-9b651a2028f3&cKey= a8db6616-5ef8-484f-b65e-4e1d48fcfdac&mKey=0C918954-D607-46A7-8073- 44F4B537A439. Accessed October 8, 2013.
23. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952-962.
24. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4: 144-154.
25. Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5:e1000476.
26. Niedzielski A, Korona-Głowniak I, Malm A, et al. Distribution of vaccine serotypes among Streptococcus pneumoniae colonizing the upper respiratory tract in healthy pre-school children in south-east Poland. Otolaryngol Pol. 2012;66:403-406.
27. Valente C, Hinds J, Pinto F, et al. Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine. PLoS One. 2012;7:e30235.
28. Kronenberg A, Zucs P, Droz S, et al. Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. J Clin Microbiol. 2006;44:2032-2038.
29. Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect. 2005;133:891-898.
30. Sharma D, Baughman W, Holst A, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J. 2013;32:e45-e53.
31. Brueggemann AB, Griffiths DT, Meats E, et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotypeand clone-specific differences in invasive disease potential. J Infect Dis. 2003;187:1424-1432.
32. Lagos R, Munoz A, San Martin O, et al. Age-and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. J Infect Dis. 2008;198:1809-1817.
33. Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25:602-607.
34. Hanage WP, Kaijalainen TH, Syrjanen RK, et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun. 2005;73:431-435.
35. Zemlickova H, Jakubu V, Urbaskova P, et al. Serotype-specific invasive disease potential of Streptococcus pneumoniae in Czech children. J Med Microbiol. 2010;59(pt 9):1079-1083.
36. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine. 2009;27:5513-5518.
37. Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30:227-233.
38. Tokarz R, Briese T, Morris G, et al. Serotype analysis of Streptococcus pneumoniae in lung and nasopharyngeal aspirates from children in the Gambia by MassTag PCR. J Clin Microbiol. 2013;51:995-997.
39. Dagan R, Trammer J, Patterson S, et al. Efficacy of 13-valent versus 7-valent pneumococcal conjugate vaccine (PCV13, PCV7) in preventing nasopharyngeal colonization of antibiotic resistant S. pneumoniae (ARSP). Paper presented at: [31st Annual Meeting of the European Society for Paediatric Infectious Diseases; May 26-June 1, 2013; Milan, Italy. 2013. Available at: http://www.sessionplan.com/espid2013/. Accessed June 14, 2013.
40. Grivea IN, Sourla A, Ntokou E, et al. Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece. BMC Infect Dis. 2012;12:255.
41. Grivea IN, Tsantouli AG, Michoula AN, et al. Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece. Vaccine. 2011;29: 8882-8887.
42. Camilli R, Daprai L, Cavrini F, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One. 2013;8:e76309.
43. Dagan R, Greenberg D, Leibovitz E, et al. Trends in serotype-specific pneumococcal carriage in children visting emergency room (PER) post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media incidence (OM). Paper presented at: ID Week 2013; October 2-6, 2013; San Francisco, CA. 2013. Available at: https:// idsa.confex.com/idsa/2013/ webprogram/Paper39980.html. Accessed September 12, 2013.
44. Azzari C, Moriondo M, Indolfi G, et al. Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease. PLoS One. 2010;5:e9282.
45. Pasinato A, Indolfi G, Marchisio P, et al.; Italian Group for the Study of Bacterial Nasopharyngeal Carriage in Children. Pneumococcal serotype distribution in 1315 nasopharyngeal swabs from a highly vaccinated cohort of Italian children as detected by RT-PCR. Vaccine. 2014;32:1375-1381.
46. Weinberger DM, Givon-Lavi N, Shemer-Avni Y, et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis. 2013;19:1084-1091.
47. Dagan R, Ben-Shimol S, Greenberg D, et al. PCV13 has an additional impact beyond that of PCV7 on incidence and antibiotic-resistance in otitis media (OM) in children 2 years. Abstract G-1451. Paper presented at: 53rd ICAAC; September 10-13, 2013; Denver, CO. 2013. Available at: http://www.abstractsonline.com/ Plan/ViewAbstract. aspx?sKey=49cb1df8-6999-459f-a478-e23cc2dca2d6&cKey= a98d5fd9-d46c-4398-bbb2-7a769c63c5bc&mKey=%7b7DD36E88-52C3-4FF1-A5DF- 1D00766558B8%7d. Accessed September 12, 2013.
48. Dagan R, Givon-Lavi N, Leibovitz E, et al. Rapid reduction in the incidence of culture-positive nonsusceptible Streptococcus pneumoniae (NSSP) otitis media (AOM) following introduction of pneumococcal conjugate vaccines (PCVs) in Southern Israel. Paper presented at: 52nd ICAAC; September 9-12, 2012; San Francisco, CA, USA. 2012. Abstract G-1050. Available at: http://www.abstractsonline.com/Plan/ViewAbstract. aspx?sKey=7cc8a70d-9b35-49a7- b9c9-83b649b9db28&cKey=63ceb92bbea2-4b0f-afee-94b26ee72502&mKey= %7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d. Accessed July 9, 2013.
49. Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging. 1999;15 (suppl 1):11-19.
50. Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102-1106.
51. Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mortal Wkly Rep. 2009;58:1-4.
52. Centers for Disease Control and Prevention (CDC). Outbreak of pneumococcal pneumonia among unvaccinated residents of a nursing home-New Jersey, April 2001. MMWR Morb Mortal Wkly Rep. 2001;50:707-710.
53. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49:1815-1827.
54. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68:1057-1065.
55. Rose MA, Christopoulou D, Myint TT, et al. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract. 2014;68:8-19.
56. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65:17-24.
57. Madhi SA, Petersen K, Madhi A, et al. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J. 2000;19:1141-1147.
58. Mao C, Harper M, McIntosh K, et al. Invasive pneumococcal infections in human immunodeficiency virus-infected children. J Infect Dis. 1996;173:870-876.
59. Steenhoff AP, Wood SM, Rutstein RM, et al. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006. Pediatr Infect Dis J. 2008;27:886-891.
60. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562-569.
61. Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. Pediatrics. 2006;117:284-289.
62. Rose MA, Christopoulou D, Myint TT, et al. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract. 2014;68:8-19.
63. Cohen AL, Harrison LH, Farley MM, et al.; Active Bacterial Core Surveillance Team. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS. 2010;24:2253-2262.
64. De Montalembert M, Abboud MR, Fiquet A, et al. 3212 A 2-dose schedule of 13-valent pneumococcal conjugate vaccine (PCV13) given to children with sickle cell disease previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. Paper presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA, USA. 2012. Available at: https://ash.confex.com/ ash/2012/webprogram/Paper46811.html. Accessed June 14, 2013.
65. Martinon-Torres F, Center KJ, Czajka H, et al. [4510.190] Immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in preterm (PT) infants compared with full-term (FT) infants. Paper presented at: Annual Meeting of the Pediatric Academic Societies (PAS) 2013; May 4-7, 2013; Washington, DC, USA. 2013. Available at: http://www.abstracts2view.com/ pas/view.php?nu=PAS13L1-4510. 190. Accessed June 14, 2013.
66. Glesby MJ, Brinson CC, Greenberg RN, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate caccine in HIV+ adults with prior 23-valent pneumococcal polysaccharide vaccination. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2013; Atlanta, GA, USA. 2013. Available at: http://www.retroconference. org/2013b/PDFs/880.pdf. Accessed June 14, 2013.
67. European Centre for Disease Prevention and Control. Recommended immunisations for pneumococcal disease. [ECDC Network]. 2014. Available at: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx. Accessed January 20, 2014.
68. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Changes in incidence of serotype-specific presentations of invasive pneumococcal disease following switch from PCV7 to PCV13 for universal vaccination. Paper presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; May 26-June 1, 2013; Milan, Italy. 2013. Available at: http://www.abstractserver. com/espid2013/planner/index. php?go=abstract&action=abstract- iplanner&print=1&lprID=199&highlight=Picazo&PSID= QLZZYDSXCMRCHOAVERDF&ESPID2013=q9s0pc vfomnko2i63i6lrvqevbvtrion. Accessed June 14, 2013.
69. Gervaix A, Ansaldi F, Brito-Avo A, et al. Pneumococcal Vaccination in Europe: Schedule Adherence. Clin Ther. 2014;36:802-812.
70. Rodgers GL, Esposito S, Principi N, et al. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013;31:4765-4774.
71. Department of Health. Pneumococcal polysaccharide vaccine (PPV) uptake summary report. Available at: [https://www.wp.dh.gov.uk/immunisation/ files/2012/08/2900139-PPV-UptakeSummaryReport2012-acc2 pdf]. August 6, 2012. Accessed March 4, 2013.
72. Schweizerische Eidgenossenschaft. Couverture vaccinale des enfants ages de 2, 8 et 16 ans en Suisse, 2008-2010. [Schweizerische Eidgenossenschaft]. October 1, 2012. Available at: http://www.bag.admin. ch/themen/medizin/00682/ 00685/02133/index.html?lang=fr. Accessed June 14, 2013.
73. Institut de Veille Sanitaire. Couverture par le vaccine. [Institut de Veille Sanitaire]. March 7, 2012. Available at: http:// www.invs.sante.fr/ Dossiersthematiques/ Maladies-infectieuses/Maladies-A-prevention-vaccinale/ Couverture-vaccinale/Donnees. Accessed June 14, 2013.
74. PediSurv. Le rapport d'activite annuel 2010. [PediSurv]. 2010. Available at: https://www.wiv-isp.be/pedisurv/f-index.htm. Accessed June 14, 2013.
75. Giotas A, Kotzia D, Grivea IN, et al. Timeliness of pneumococcal conjugate vaccination in Greece. Paper presented at: 30th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 8-12, 2012; Thessaloniki, Greece. 2012. Available at: http://www.kenes.com/espid2012/ abstracts/PDF/862.pdf?zoom-highlightsub=Giotas#search="Giotas". Accessed June 14, 2013.
76. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:689-696.
77. Martinot A, Cohen R, Denis F, et al. [Annual trends (2008-2011) in early childhood vaccination coverage for the French population: the Vaccinoscopie(R) study]. Arch Pediatr. 2013;20:837-844.
78. Hug S, Weibel D, Delaporte E, et al. Comparative coverage of supplementary and universally recommended immunizations in children at 24 months of age. Pediatr Infect Dis J. 2012;31:217-220.
79. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al.; HERACLES Study Group. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age-and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol. 2013;20:1524-1530.
80. Leask J. Target the fence-sitters. Nature. 2011;473:443-445.
81. Braeckman T, Lernout T, Top G, et al. Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: achieving the best of both worlds. Vaccine. 2014;32:345-349.
82. Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis. 2013;19:1074-1083.